5.2 Million Dengue Vaccines Arriving in Brazil

The Federative Republic of Brazil's Ministry of Health recently confirmed it is the first country in the world to offer Takeda's QDENGA® dengue vaccine in a universal public system. 

QDENGA (TAK-003) is a tetravalent vaccine [Live, Attenuated] that does not require pre-admision testing.

As of January 15, 2024, the Ministry of Health forecasts that 5.2 million doses will be delivered between February and November 2024.

The current expectation is that around 3.2 million people will be vaccinated in 2024.

In 2023, the WHO's Strategic Advisory Group of Experts on Immunization confirmed QDENGA had demonstrated efficacy against all four serotypes of the dengue virus in baseline seropositive children (4-16 years) in endemic countries and against serotypes 1 and 2 in baseline seronegative children.

As of January 17, 2024, QDENGA is authorized in several countries but not the United States.